Agent | Molecular target | Molecular effect | Specific side effects | Comments |
---|---|---|---|---|
ATG/ALG | Binds multiple antigens on lymphoid cells | Complement-mediated lysis | Serum sickness | Batch variability |
 |  | Opsonization and clearance | Thrombocytopenia |  |
 |  | Modification of cell surface receptor | Granulocytopenia |  |
OKT3 | Binds T cell CD3 | Complement mediated lysis | Cytokine release syndrome | Tachyphylaxis due to anti-idiotypic antibodies |
 |  | Opsonization and clearance | (eg fever, chills, headache, and pulmonary edema) |  |
 |  | Modification of CD3 receptor |  |  |
Daclizumab | Binds α-subunit of interleukin-2 receptor | Down-regulation of receptor | No major side effects reported so far | Humanized antibody |
 |  | ? CD4 T cell depletion |  | Long half-life (20 days) |
 |  |  |  | Five-dose regimen |
Basiliximab | Binds α-subunit of interleukin-2 receptor | Down-regulation of receptor | No major side effects reported so far | Chimeric antibody |
 |  | ? CD4 T cell depletion |  | Long half-life (10-14 days) |
 |  |  |  | Two-dose regimen |